[{"id":"512f11f2-4e13-4446-8636-e0eea75d8423","acronym":"","url":"https://clinicaltrials.gov/study/NCT02369198","created_at":"2021-01-18T11:17:01.373Z","updated_at":"2024-07-02T16:37:23.697Z","phase":"Phase 1","brief_title":"MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC","source_id_and_acronym":"NCT02369198","lead_sponsor":"Asbestos Diseases Research Foundation","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TargomiR (EGFREDVmiR-16)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 01/04/2017","primary_completion_date":" 01/04/2017","study_txt":" Completion: 01/04/2017","study_completion_date":" 01/04/2017","last_update_posted":"2017-04-07"}]